In patients with renal cell carcinoma (RCC), overexpression of SLAMF2, CD85, CD45, and PD-1 characterizes a predominantly inhibitory phenotype in circulating and tumor-infiltrating NK cells (134). This evidence concerns the gene PTPRC and renal cell carcinoma.